Exciting Progress | Gritgen Therapeutics Completed Patients Enrollment in China’s First Gene Therapy Investigator-Initiated Trial for Hemophilia A and also Achieved the First Patient Dosed in China Phase I Trial in Patients with Severe Hemophilia A

16/11/2023 — SUZHOU, China — (BUSINESS WIRE) Gritgen Therapeutics Co., Ltd. (Gritgen), a biotechnology company focused on identifying and developing innovative gene therapy products to achieve “Great Science for Human […]